Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater

被引：0

作者：

Tambo, Yuichi ^{[1
]}

Sone, Takashi ^{[1
]}

Shibata, Kazuhiko ^{[2
]}

Nishi, Kouichi ^{[3
]}

Shirasaki, Hiroki ^{[4
]}

Yoneda, Taro ^{[5
]}

Araya, Tomoyuki ^{[6
]}

Kase, Kazumasa ^{[7
]}

Nishikawa, Shingo ^{[1
]}

Kimura, Hideharu ^{[1
]}

Kasahara, Kazuo ^{[1
]}

机构：

[1] Kanazawa Univ Hosp, Resp Med, Kanazawa, Ishikawa, Japan

[2] Kouseiren Takaoka Hosp, Dept Med Oncol, Takaoka, Toyama, Japan

[3] Ishikawa Prefectural Cent Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan

[4] Fukui Ken Saiseikai Hosp, Dept Resp Med, Fukui, Japan

[5] Komatsu Municipal Hosp, Dept Resp Med, Komatsu, Japan

[6] Natl Hosp Org Kanazawa Med Ctr, Dept Resp Med, Kanazawa, Ishikawa, Japan

[7] Keiju Med Ctr, Dept Internal Med, Nanao, Japan

来源：

关键词：

D O I：

10.1016/j.annonc.2021.05.626

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO25-3

引用

页码：S313 / S313

页数：1